C12N 2310/31
Of the backbone
Official title: of the backbone
C12N2310/31 (Of the backbone) appears on 4,207 US grants and 7,694 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,207
- Published applications
- 7,694
- Assignees
- 1,484
- Inventors
- 7,741
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 4 | 0 |
| 1993 | 7 | 0 |
| 1994 | 5 | 0 |
| 1995 | 11 | 0 |
| 1996 | 35 | 0 |
| 1997 | 84 | 0 |
| 1998 | 73 | 0 |
| 1999 | 112 | 0 |
| 2000 | 137 | 0 |
| 2001 | 126 | 20 |
| 2002 | 126 | 87 |
| 2003 | 72 | 364 |
| 2004 | 65 | 354 |
| 2005 | 40 | 276 |
| 2006 | 50 | 166 |
| 2007 | 48 | 152 |
| 2008 | 47 | 103 |
| 2009 | 74 | 188 |
| 2010 | 109 | 180 |
| 2011 | 124 | 179 |
| 2012 | 131 | 183 |
| 2013 | 118 | 176 |
| 2014 | 133 | 216 |
| 2015 | 177 | 294 |
| 2016 | 177 | 302 |
| 2017 | 192 | 300 |
| 2018 | 193 | 325 |
| 2019 | 234 | 366 |
| 2020 | 232 | 376 |
| 2021 | 230 | 431 |
| 2022 | 221 | 509 |
| 2023 | 196 | 554 |
| 2024 | 219 | 596 |
| 2025 | 232 | 570 |
| 2026 | 172 | 427 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2310/315PhosphorothioatesIndexing code3,465
- C12N 2310/318Where the po2 is completely replacedIndexing code537
- C12N 2310/314PhosphoramidatesIndexing code429
- C12N 2310/317With an inverted bondIndexing code386
- C12N 2310/312PhosphonatesIndexing code353
- C12N 2310/313PhosphorodithioatesIndexing code173
- C12N 2310/316PhosphonothioatesIndexing code71
- C12N 2310/311PhosphotriestersIndexing code54
All 9 subgroupsShow fewer
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- OPA1 antisense oligomers for treatment of conditions and diseases6 Oct 2026US 12,753,408 B2Stoke Therapeutics, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- MRNA 5′-end cap analogs modified within phosphate residues, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide29 Sep 2026US 12,747,261 B2Explorna Therapeutics Sp. z o.o.
- Optimized gapmers antisense oligonucleotides for increasing foxg1 expression8 Oct 2026US 2026/0308582 A1EliGab Tx LLC
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)8 Oct 2026US 2026/0308585 A1Alnylam Pharmaceuticals, Inc.
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Antisense oligonucleotide modulation of multidrug resistance-associated protein841US 5,801,154 AIsis Pharmaceuticals, Inc. · 1998
- N-2 substituted purines806US 5,459,255 AIsis Pharmaceuticals, Inc. · 1995
- Peptide nucleic acids763US 5,539,082 A1996
- Inhibition of cell proliferation using antisense oligonucleotides753US 5,756,476 AThe United States of America as represented by the Department of Health and Human Services · 1998
- Inhibitors for replication of retroviruses and for the expression of oncogene products698US 5,264,423 AThe United States of America as represented by the Department of Health and Human Services · 1993